Retrospective analyses of data from the Suppression of Ovarian Function Trial trial, led by Hologic Inc. and its subsidiary, Biotheranostics Inc., showed that the Breast Cancer Index test identified which premenopausal patients with early-stage, hormone-receptor positive breast cancer benefited from the addition of ovarian function suppression to primary adjuvant endocrine therapy.
Hope S. Rugo has joined City of Hope to lead its Women’s Cancers Program throughout the organization and breast medical oncology division section.
